Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. In-vivo gentamicin susceptibility test for prevention of bacterial biofilms in bone tissue and on implants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Erratum for Hertz et al., "Antibiotic Selection of Escherichia coli Sequence Type 131 in a Mouse Intestinal Colonization Model"

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antibiotic prescribing in paediatric inpatients in Ghana: a multi-centre point prevalence survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Traffic flow and microbial air contamination in operating rooms at a major teaching hospital in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Schistosomiasis Presenting as Recurring Sigmoid Volvulus in a Danish Man With an Inconspicuous Travel History-A Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Amodiaquine plus artesunate is the recommended antimalarial treatment in many countries where malaria is endemic. However, pediatric doses are largely based on a linear extrapolation from adult doses. We pooled data from previously published studies on the pharmacokinetics of amodiaquine, to optimize the dose across all age groups. Adults and children with uncomplicated malaria received daily weight-based doses of amodiaquine or artesunate-amodiaquine over 3 days. Plasma concentration-time profiles for both the parent drug and the metabolite were characterized using nonlinear mixed-effects modeling. Amodiaquine pharmacokinetics were adequately described by a two-compartment disposition model, with first-order elimination leading to the formation of desethylamodiaquine, which was best described by a three-compartment disposition model. Body size and age were the main covariates affecting amodiaquine clearance. After adjusting for the effect of weight, clearance rates for amodiaquine and desethylamodiaquine reached 50% of adult maturation at 2.8 months (95% confidence interval [CI], 1.5 to 3.7 months) and 3.9 months (95% CI, 2.6 to 5.3 months) after birth, assuming that the baby was born at term. Bioavailability was 22.4% (95% CI, 15.6 to 31.9%) lower at the start of treatment than during convalescence, which suggests a malaria disease effect. Neither the drug formulation nor the hemoglobin concentration had an effect on any pharmacokinetic parameters. Results from simulations showed that current manufacturer dosing recommendations resulted in low desethylamodiaquine exposure in patients weighing 8 kg, 15 to 17 kg, 33 to 35 kg, and >62 kg compared to that in a typical 50-kg patient. We propose possible optimized dosing regimens to achieve similar drug exposures among all age groups, which require further validation.

Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number10
Pages (from-to)e02193-17
ISSN0066-4804
DOIs
Publication statusPublished - Oct 2018

ID: 56599702